Kausik K. Ray

United Nations Industrial Development Organization — Austria

Medicine · Health Sciences

120h-index85.7kcitations839works8.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(482), Health Systems, Economic Evaluations, Quality of Life(165), Diabetes, Cardiovascular Risks, and Lipoproteins(148), Cancer, Lipids, and Metabolism(105), Pharmaceutical Economics and Policy(80)

Publications821 total

Expert Opinion on Targeted Lipid Control for Very-high-risk Indian Patients: Bridging the Gap in Real-world Practice
European Cardiology Review·2025Open Access
Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study
Revista Portuguesa de Cardiologia·2025Open Access
Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial
European Heart Journal - Digital Health·2025Open Access
Anxiety and depression and secondary prevention of coronary heart disease in 14 countries across six WHO regions: the INTERASPIRE study
European Journal of Preventive Cardiology·2025· 1 citedOpen Access
Abstract 4368890: Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials
Circulation·2025· 1 cited
Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study
Irish Journal of Medical Science (1971 -)·2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
The Journal of Prevention of Alzheimer s Disease·2025· 4 citedOpen Access
Challenges in achieving LDL-C goals: Insights from the Italian SANTORINI study cohort
Nutrition Metabolism and Cardiovascular Diseases·2025· 1 cited
A Comprehensive Narrative Review Designed to Evaluate the Health Benefits of Apples and Their Derivatives, with a Focus on Cardiovascular Disease (CVD) Prevention, Metabolic Regulation, and Chronic Disease Mitigation
International Journal For Multidisciplinary Research·2025Open Access
Factors associated with elevated high-sensitivity C-reactive protein levels in individuals with atherosclerotic cardiovascular disease in the USA and the UK
European Journal of Preventive Cardiology·2025· 1 citedOpen Access
Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid
JACC Advances·2025· 1 citedOpen Access
AN INSIGHT INVESTIGATION ON STEADY-STATE PHARMACOKINETICS OF LOBEGLITAZONE-LOADED DISSOLVING MICRONEEDLES IN RATS
Asian Journal of Pharmaceutical and Clinical Research·2025Open Access
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Journal of the American College of Cardiology·2025· 21 citedOpen Access
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidemias - Advancing evidence-based care through innovation
Atherosclerosis·2025· 3 citedOpen Access
Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regions
European Journal of Cardiovascular Nursing·2025· 2 citedOpen Access
Physician perspectives on Lp(a) testing and management in patients with cardiovascular disease: interviews from seven countries across five world health organization regions from INTERASPIRE
European Journal of Preventive Cardiology·2025· 1 citedOpen Access
Uso de fármacos hipolipemiantes en pacientes con alto y muy alto riesgo cardiovascular en España: un año de seguimiento de la subpoblación española del estudio europeo SANTORINI
Revista Clínica Española·2025· 1 citedOpen Access
Lipoprotein(a) Levels and Time to Cardiovascular Benefit With Alirocumab in Patients With Recent Acute Coronary Syndrome
Journal of the American College of Cardiology·2025· 2 cited
Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Atherosclerosis·2025· 10 citedOpen Access
Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial
American Journal of Cardiovascular Drugs·2025· 1 citedOpen Access
page 1 of 42Next →

Frequent Co-authors

Alberico L. Catapano(25), Henry N. Ginsberg(18), Frederick J. Raal(15), Børge G. Nordestgaard(15), Gerald F. Watts(14), Olov Wiklund(13), Erik S.G. Stroes(13), Robert A. Hegele(13), M. John Chapman(13), Marja‐Riitta Taskinen(12), L. Masana(12), Éric Bruckert(11), Lawrence A. Leiter(11), Raúl D. Santos(11), Brian A. Ference(10), Lâle Tokgözoğlu(10), Jan Borén(10), Olivier Descamps(10), Ulf Landmesser(9), Stephen J. Nicholls(9)